RARA CRAFT DATABASE for FDA Medical Devices
510(k)K190219

FDA DEVICE FACTS

Simplexa VZV Direct, Simplexa VZV Positive Control Pack

Diasorin Molecular, LLC

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEMay 13, 2019PRODUCT CODEPLO

Indications for use

Simplexa™ VZV Direct REF MOL3650 The DiaSorin Molecular Simplexa™ VZV Direct assay is intended for use on the LIAISON ® MDX instrument for the qualitative detection of varicella- zoster virus (VZV) DNA in cerebrospinal fluid (CSF) from patients with signs a nd/or symptoms of meningitis and/or encephalitis . This test is intended as an aid in the diagnosis of VZV infections of the central nervous system (CNS). Negative results do not preclude VZV infection and should not be used as the sole basis for treatment or other patient management decisions. The assay is not intended for use as a donor screening test. The assay is for professional use only. Simplexa™ VZV Positive Control Pack REF MOL3660 The Simplexa™ VZV Positive Control Pack is intended to be used as a control with the Simplexa™ VZV Direct kit. This control is not intended for use with other assays or systems.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 25, 2026